A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A monoclonal gammopathy of undetermined significance (MGUS) occurs in up to 2 percent of persons 50 years of age or older. Reliable predictors of progression have not been identified, and information on prognosis is limited. METHODS: We identified 1384 patients residing in southeastern Minnesota in whom MGUS was diagnosed at the Mayo Clinic from 1960 through 1994. The primary end point was progression to multiple myeloma or another plasma-cell cancer. RESULTS: During 11,009 person-years of follow-up, MGUS progressed in 115 of the 1384 patients to multiple myeloma, IgM lymphoma, primary amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, or plasmacytoma (relative risk of progression, 25.0, 2.4, 8.4, 46.0, 0.9, and 8.5, respectively). The overall relative risk of progression was 7.3 in these patients as compared with the white population of the Iowa Surveillance, Epidemiology, and End Results program. In 32 additional patients, the monoclonal protein concentration increased to more than 3 g per deciliter or the percentage of plasma cells in the bone marrow increased to more than 10 percent (smoldering multiple myeloma) but without progression to overt myeloma or related disorders. The cumulative probability of progression was 12 percent at 10 years, 25 percent at 20 years, and 30 percent at 25 years. The initial concentration of serum monoclonal protein was a significant predictor of progression at 20 years. CONCLUSIONS: The risk of progression of MGUS to multiple myeloma or related disorders is about 1 percent per year.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MGUS progresses to multiple myeloma or related malignancy a rate of 1% per year.16,17”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [16]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
History of the Rochester Epidemiology Project
Melton, L. J. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.266 · Cited by 1,443
Self-citationKyle, R., Linos, A., Beard, C., Linke, R., Gertz, M., O'Fallon, W., & Kurland, L. (1992) · Blood · doi:10.1182/blood.v79.7.1817.1817 · Cited by 657
Self-citationMonoclonal gammopathy of undetermined significance
Kyle, R. A. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90522-3 · Cited by 607
Self-citationFrequency of Pathological Proteins (M‐components) in 6,995 Sera from an Adult Population
AXELSSON, U., BACHMANN, R., & HÄLLÉN, J. (1966) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1966.tb05453.x · Cited by 436
“Benign” Monoclonal Gammopathy—After 20 to 35 Years of Follow-Up
KYLE, R. A. (1993) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60015-9 · Cited by 338
Self-citationThe Analysis of Mortality by the Subject-Years Method
Berry, G. (1983) · Biometrics · doi:10.2307/2530817 · Cited by 278
Research works printed but not linked: 4
- Hallen J, 1966, Acta Med Scand Suppl, 462, 1
- Kyle RA, Katzmann JA. Immunochemical characterization of immunoglobulins. In: Rose NR, Conway de Macario E, Folds JD, Lane HC, Nakamura RM, eds. Manual of clinical laboratory immunology. 5th ed. Washington, D.C.: ASM Press, 1997:156-76.
- Kyle RA, 1999, Blood, 94, 537a
- Fonseca R, 1999, Blood, 94, 663a
Cited by
Items 601–700 of 1,000
Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients
Bosseboeuf, A., Seillier, C., Mennesson, N., Allain‐Maillet, S., Fourny, M., Tallet, A., Piver, É., Lehours, P., Mégraud, F., Berthelot, L., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00854 · Cited by 17
Malignant transformation in IgM monoclonal gammopathy of undetermined significance
Montoto, S., Rozman, M., Rosiñol, L., Nadal, E., Giné, E., Aymerich, M., Ferrer, A., Esteve, J., Bosch, F., López‐Guillermo, A., et al. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50067 · Cited by 17
Monoclonal Gammopathy of Undetermined Significance
Fiegl, M., & Greil, R. (2002) · New England Journal of Medicine · doi:10.1056/nejm200206273462614 · Cited by 17
Wang, L., Kumar, M., Deng, Q., Wang, X., Liu, M., Gong, Z., Zhang, S., Ma, X., Xu-Monette, Z. Y., Xiao, M., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2018.10.009 · Cited by 16
“The risk of progression from MGUS to multiple myeloma is estimated to be 1% per year [3, 4].”
BackgroundPeptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy
Biri‐Kovács, B., Bánóczi, Z., Tummalapally, A., & Szabó, I. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020452 · Cited by 19
Stern, S., Chaudhuri, S., Drayson, M. T., Henshaw, S., Karunanithi, K., Willis, F. M., & the Haemato‐Oncology Task Force of the British Society for Haematology and the UK Myeloma Forum (2023) · British Journal of Haematology · doi:10.1111/bjh.18866 · Cited by 22
Genetic Factors and Pathogenesis of Waldenström’s Macroglobulinemia
Monge, J., Braggio, E., & Ansell, S. M. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0331-7 · Cited by 16
González‐Calle, V., & Mateos, M. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.05.029 · Cited by 18
Renal-limited AL amyloidosis – a diagnostic and management dilemma
Fuah, K. W., & Lim, C. T. S. (2018) · BMC Nephrology · doi:10.1186/s12882-018-1118-8 · Cited by 16
van Kruijsdijk, R. C. M., Abrahams, A. C., Nguyen, T. Q., Minnema, M. C., Jacobs, J. F. M., & Limper, M. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00723-2 · Cited by 16
Ravindran, A., Lackore, K. A., Glasgow, A. E., Drake, M. T., Hobbs, M., Kourelis, T., Kumar, S. K., Kyle, R. A., Leung, N., Muchtar, E., et al. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.12.033 · Cited by 17
Self-citationPlasmacytoid Dendritic Cells in Patients with MGUS and Multiple Myeloma
Knight, A., Říhová, L., Králová, R., Penka, M., Adam, Z., Pour, L., Piskáček, M., & Hájek, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163717 · Cited by 16
“On average, about 1% of MGUS patients will go on to develop MM each year [27,28].”
BackgroundMonoclonal gammopathy of renal significance: Multidisciplinary approach to diagnosis and treatment
Karam, S., Haidous, M., Dalle, I. A., Dendooven, A., Moukalled, N. M., Craenenbroeck, A. H. V., Bazarbachi, A. A., & Sprangers, B. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103926 · Cited by 18
Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma
Mitsiades, C. S., & Chen‐Kiang, S. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.014 · Cited by 16
Monoclonal and biclonal gammopathy in two patients infected with Bartonella henselae
Krause, R. G. E., Auner, H. W., Daxböck, F., Mulabecirovic, A., Krejs, G. J., Wenisch, C., & Reisinger, E. C. (2003) · Annals of Hematology · doi:10.1007/s00277-003-0675-4 · Cited by 17
“In order to avoid unnecessary invasive or cost-intensive diagnostic procedures, it is important to identify risk factors such as the initial immunoglobulin level or erythrocyte sedimentation rate [2].”
BackgroundAustin, S. K., Cohen, H., & Losseff, N. A. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.092023 · Cited by 16
“MGUS is characterised by the presence of an elevated paraprotein level without any evidence of another plasma cell disorder or lymphoproliferative disease. It is a common finding (1% in ages >50 years, 3% in ages >70 years), with a relatively good prognosis although approximately 1–3% of MGUS cases per year progress i…”
BackgroundSmoldering multiple myeloma and monoclonal gammopathy of undetermined significance
Bladé, J., & Rosiñol, L. (2006) · Current Treatment Options in Oncology · doi:10.1007/s11864-006-0016-7 · Cited by 17
Engels, E. A., Savoldo, B., Pfeiffer, R. M., Costello, R., Zingone, A., Heslop, H. E., & Landgren, O. (2012) · Transplantation · doi:10.1097/tp.0b013e318274ab63 · Cited by 16
“, monoclonal gammopathy of undetermined significance [MGUS]) indicates the presence of an abnormal clone of plasma cells and is associated with development of multiple myeloma (13).”
BackgroundZemble, R., Takach, P. A., & Levinson, A. I. (2011) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9548-0 · Cited by 16
Gammapatías biclonales: estudio retrospectivo de 47 pacientes
García-García, P., Enciso-Alvarez, K., Díaz‐Espada, F., Vargas, J. A., Moraru, M., & Yebra‐Bango, M. (2014) · Revista Clínica Española · doi:10.1016/j.rce.2014.07.003 · Cited by 16
Understanding the molecular biology of myeloma and its therapeutic implications
Boyd, K. D., Pawlyn, C., Morgan, G. J., & Davies, F. E. (2012) · Expert Review of Hematology · doi:10.1586/ehm.12.51 · Cited by 21
Precursors to Lymphoproliferative Malignancies
Goldin, L. R., McMaster, M. L., & Caporaso, N. E. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-1348 · Cited by 17
“Following 3 decades of research, 3 distinct clinical subtypes of MGUS have been defined: non-IgM MGUS, IgM MGUS, and light-chain MGUS.”
BackgroundInfluentialIs there an association between multiple myeloma and prostate cancer?
Kao, J., Jani, A. B., & Vijayakumar, S. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2003.10.029 · Cited by 17
“15% of the general population and over a period of 30 years, up to 16% will develop multiple myeloma, usually after accumulating additional mutations [4,5].”
BackgroundRisk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics
Clay‐Gilmour, A., Kumar, S. K., Rajkumar, S. V., Rishi, A. R., Kyle, R. A., Katzmann, J. A., Murray, D. L., Norman, A. D., Greenberg, A. J., Larson, D. R., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0246-2 · Cited by 17
Self-citationTreatment of Smoldering Multiple Myeloma: Ready for Prime Time?
Kim, E. B., Yee, A. J., & Raje, N. S. (2020) · Cancers · doi:10.3390/cancers12051223 · Cited by 17
Kristinsson, S. Y., Goldin, L. R., Björkholm, M., Turesson, I., & Landgren, O. (2009) · Haematologica · doi:10.3324/haematol.2009.006346 · Cited by 16
“Long-term follow-up of MGUS patients reveals an average 1% annual risk of developing a lymphoproliferative malignancy.(3,4) Although the etiology of MM and MGUS is unknown, there is emerging evidence to support a role for genetic factors.”
BackgroundWeiss, B. M., & Kuehl, W. M. (2010) · Expert Review of Hematology · doi:10.1586/ehm.10.13 · Cited by 18
Monoclonal gammopathy: natural history studied with a retrospective approach
Steingrimsdottir, H., Haraldsdóttir, V., Ólafsson, I. H., Gudnason, V. G., & Ogmundsdottir, H. M. (2007) · Haematologica · doi:10.3324/haematol.11284 · Cited by 16
“In the Kyle series, only the concentration and type of monoclonal protein were independent predictors of progression showing that patients with IgM and IgA paraprotein had an increased risk of developing malignant disease.(5) Several smaller studies showed similar results with a higher probability of progression for I…”
BackgroundResultDiseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus
(2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0792-2.50018-3 · Cited by 20
Roos, A. J. D., Baris, D., Weiss, N. S., & Herrinton, L. J. (2006) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195149616.003.0047 · Cited by 20
Rodriguez, A. L., Tariman, J. D., Enecio, T., & Estrella, S. M. (2007) · Clinical journal of oncology nursing · doi:10.1188/07.cjon.579-589 · Cited by 16
“…rule out MM. MM must be distinguished from monoclonal gammopathy of undetermined signifi cance or smoldering and indolent MM, which usually requires observation only until the disease transforms into symptomatic, active myeloma (Kyle et al., 2002; National Comprehensive Cancer Network, 2005).”
BackgroundZhan, F., Barlogie, B., & Shaughnessy, J. D. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)00197-5 · Cited by 16
Treatment of multiple myeloma: An emphasis on new developments
Kyle, R. A., & Rajkumar, S. V. (2006) · Annals of Medicine · doi:10.1080/07853890500472078 · Cited by 16
“It needs to be distinguished from monoclonal gammopathy of undetermined significance (3) and smoldering multiple myeloma (4).”
BackgroundSelf-citationStorti, F. (2008) · Cited by 16
Sinit, R. B., Hwang, D. G., Vishnu, P., Peterson, J. F., & Aboulafia, D. M. (2019) · BMC Cancer · doi:10.1186/s12885-019-6286-9 · Cited by 18
“, additional genetic changes from chronic antigenic stimulation or exposure to toxins, cell cycle dysregulation, or changes in the bone marrow microenvironment [4, 5].”
BackgroundSaade, C., & Ghobrial, I. M. (2025) · La Presse Médicale · doi:10.1016/j.lpm.2025.104268 · Cited by 15
Messori, A., Maratea, D., Nozzoli, C., & Bosi, A. (2011) · PharmacoEconomics · doi:10.2165/11585930-000000000-00000 · Cited by 15
Methylation of tumor suppressor microRNAs: lessons from lymphoid malignancies
Wang, L. Q., Liang, R. H. S., & Chim, C. S. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.64 · Cited by 16
Imaging of Multiple Myeloma: Usefulness of MRI and PET/CT
Koppula, B. R., Kaptuch, J. M., & Hanrahan, C. J. (2013) · Seminars in Ultrasound CT and MRI · doi:10.1053/j.sult.2013.05.006 · Cited by 15
Prevalence of Monoclonal Gammopathy of Undetermined Significance in India—A Hospital-based Study
Gupta, R., Dahiya, M., Kumar, L., Shekhar, V., Sharma, A., Ramakrishnan, L., Sharma, O. D., & Begum, A. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.06.005 · Cited by 15
Decaux, O., Rodon, P., Ruelland, A., Estepa, L., Leblay, R., & Grosbois, B. (2007) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2007.04.011 · Cited by 18
Wolff, F., Thiry, C., & Willems, D. (2006) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2006.11.011 · Cited by 16
Duek, A., Trakhtenbrot, L., Avigdor, A., Nagler, A., & Leiba, M. (2020) · Acta Haematologica · doi:10.1159/000507414 · Cited by 17
Chavda, S. J., & Yong, K. (2017) · British Journal of Hospital Medicine · doi:10.12968/hmed.2017.78.2.c21 · Cited by 15
Management of Newly Diagnosed Myeloma
Rajkumar, S. V., & Palumbo, A. P. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.08.008 · Cited by 17
Self-citationGlomerular and Tubulointerstitial Diseases
Beck, L. H., & Salant, D. J. (2008) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2008.01.002 · Cited by 19
Multiple myeloma: the disease and its treatment
Gupta, M., Pal, R. N., & Tikoo, D. (2013) · International Journal of Basic & Clinical Pharmacology · doi:10.5455/2319-2003.ijbcp20130302 · Cited by 17
Madan, S., & Greipp, P. R. (2009) · Blood Reviews · doi:10.1016/j.blre.2009.07.004 · Cited by 19
Amyloidosis presenting as lower gastrointestinal hemorrhage.
Spier, B. J., Einstein, M. M., Johnson, E. A., Zuricik, A. O., Hu, J. L., & Pfau, P. R. (2008) · PubMed · Cited by 15
Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance
Merz, M., Hielscher, T., Hoffmann, K., Seckinger, A., Hose, D., Raab, M. S., Hillengaß, J., Jauch, A. S., & Goldschmidt, H. (2018) · Leukemia · doi:10.1038/s41375-018-0202-1 · Cited by 15
Older Human B Cells and Antibodies
Dunn‐Walters, D. K., & O’Hare, J. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-64597-1_21-1 · Cited by 20
Amyloidosis: an unusual cause of upper gastrointestinal bleeding
Siau, K., Elzubeir, A., Cooper, S. C., & Iqbal, T. H. (2016) · BMJ Case Reports · doi:10.1136/bcr-2016-217653 · Cited by 14
Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects
Seth, S., Zanwar, S., Vu, L., & Kapoor, P. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00569-2 · Cited by 15
Wennmann, M., Hielscher, T., Kintzelé, L., Menze, B. H., Langs, G., Merz, M., Sauer, S., Kauczor, H., Schlemmer, H., Delorme, S., et al. (2020) · Cancers · doi:10.3390/cancers12092537 · Cited by 14
Ríos, R., Puig, N., Algarín, E. M., Silva, J. L. G. D. V., Barbosa, N., Encinas, C., Hernández‐Rivas, J., Alonso, R., Campos, M. L., Rodríguez, T., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11112020 · Cited by 15
“MP levels <30 g/L in serum or <500 mg/24 h in urine and <10% MM cells in BM define MGUS, which has an overall risk of transformation to MM of 1% per year [6].”
BackgroundVenous thromboembolism in patients with monoclonal gammopathy of undetermined significance.
Muslimani, A. A., Spiro, T. P., Chaudhry, A. A., Taylor, H. C., Jaiyesimi, I. A., & Daw, H. A. (2009) · PubMed · Cited by 15
Rawstron, A. C., Jones, R. A., Ferguson, C., Hughes, G., Selby, P., Reid, C., Dalal, S., Howard, M. R., Smith, G., Hillmen, P., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06864.x · Cited by 14
“…indolent B-cell and plasma cell disorders: a UK experience Approximately 1% of patients with monoclonal gammopathy of undeteremined significance (MGUS) or a monoclonal B-cell lymphocytosis (MBL) will show disease progression each year (Kyle et al, 2002; Rawstron et al, 2003; Marti et al, 2005).”
BackgroundPeripheral Neuropathy Associated with Lymphoma, Leukemia, and Myeloproliferative Disorders
Bosch, E. P., Habermann, T. M., & Tefferi, A. (2005) · Elsevier eBooks · doi:10.1016/b978-0-7216-9491-7.50114-9 · Cited by 14
Nomura, S., Ito, T., Yoshimura, H., Hotta, M., Nakanishi, T., Fujita, S., Nakaya, A., Satake, A., & Ishii, K. (2018) · Journal of Blood Medicine · doi:10.2147/jbm.s147743 · Cited by 14
“Introduction Multiple myeloma (MM) is an incurable malignancy of the plasma cells.(1) The majority of MM patients relapse, regardless of their initial treatment.”
Chronic intermittent hypoxia enhances disease progression in myeloma-resistant mice
Ali, M., Kowkuntla, S., Delloro, D., Galambos, C., Hathi, D., Janz, S., Shokeen, M., Tripathi, C., Xu, H., Yuk, J., et al. (2019) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00388.2018 · Cited by 16
Heavy/light chain assay in the monitoring of multiple myeloma
Ting, H. Y., Sthaneshwar, P., Bee, P. C., Shanmugam, H., & Lim, M. (2019) · Pathology · doi:10.1016/j.pathol.2019.04.002 · Cited by 14
Kim, D., Kwok, B., & Steinberg, A. S. (2010) · Southern Medical Journal · doi:10.1097/smj.0b013e3181fa5eeb · Cited by 14
“The risk of progression from MGUS to myeloma is about 1% per year, yet malignant plasma cell disorders eventually develop in about 27% of MGUS patients.(10,11) However, data from a population-based study of 17,398 patients from the Mayo Clinic noted no increased association between MGUS and acute leukemia.”
BackgroundOcio, E. M., Carpio-Jayo, D. D., Hernández-Caballero, Á., Alonso, J., Paiva, B., Pesoa, R., Villaescusa, T., López‐Anglada, L., Vídriales, M., & García‐Sánz, R. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2011.n.017 · Cited by 14
Biclonal gammopathies: Retrospective study of 47 patients
García-García, P., Enciso-Alvarez, K., Díaz‐Espada, F., Vargas-Núñez, J. A., Moraru, M., & Yebra‐Bango, M. (2014) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2014.07.004 · Cited by 14
Greenberg, A. J., Rajkumar, S. V., Larson, D. R., Dispenzieri, A. A., Therneau, T. M., Colby, C. L., Phelps, T. K., Kumar, S. K., Katzmann, J. A., Kyle, R. A., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09075.x · Cited by 14
“MGUS is a precursor for multiple myeloma (MM) and related diseases, with a rate of progression to malignancy of 1% per year (Kyle et al, 2002).”
BackgroundSelf-citationM ANAGEMENT OF M ULTIPLE M YELOMA
Harousseau, J. (2002) · Reviews in Clinical and Experimental Hematology · doi:10.1046/j.1468-0734.2002.00077.x · Cited by 14
Bergsagel, P. L. (2008) · Leukemia · doi:10.1038/leu.2008.2 · Cited by 17
Jurczyszyn, A., & Suska, A. (2019) · Reference Module in Biomedical Sciences · doi:10.1016/b978-0-12-801238-3.11412-6 · Cited by 13
Wang, M., Yu, Y., Liu, L., Schoen, M. W., Kumar, A., Vargo, K., Colditz, G. A., Thomas, T. S., & Chang, S. (2023) · JCO Clinical Cancer Informatics · doi:10.1200/cci.23.00081 · Cited by 15
YONEZAWA, S., Haruki, T., Koizumi, K., Taketani, A., Oshima, Y., Oku, M., Wada, A., Sato, T., Masuda, N., Tahara, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031570 · Cited by 16
“Approximately 5.3% of individuals older than 70 years old have MGUS [5], and about 1% of MGUS progresses to MM each year [6].”
BackgroundInfluentialGalectin-9 – ligand axis: an emerging therapeutic target for multiple myeloma
Shil, R. K., Mohammed, N. B. B., & Dimitroff, C. J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1469794 · Cited by 15
Lightbody, E. D., Sklavenitis‐Pistofidis, R., Wu, T., Tsuji, J., Firer, D. T., Agius, M. P., Dutta, A. K., Barr, H., Kim, S., Alberge, J.-B., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01006-0 · Cited by 14
Gámez, B., & Edwards, C. M. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0479-z · Cited by 13
Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma
Markus, E., Trestman, S., Cohen, Y. C., Angel, Y., Sofer, Y., Mittelman, M., Avivi, I. M., Stern, N., & Izkhakov, E. (2020) · BMC Cancer · doi:10.1186/s12885-020-06976-1 · Cited by 15
Are African primary physicians suspicious enough? Challenges of multiple myeloma diagnosis in Africa
Thokerunga, E., Ntege, C., & Ahmed, A. O. (2021) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-021-00088-3 · Cited by 13
“It is approximated that MGUS and SMM progress to full blown multiple myeloma at a rate of 1% and 10% per year respectively [33, 34].”
BackgroundRevisiting the impact of immunoglobulin isotypes in multiple myeloma
Bal, S., Giri, S., Godby, K. N., & Costa, L. J. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04783-1 · Cited by 13
“[2] Once these clonal cells acquire additional “hits” and undergo malignant transformation into multiple myeloma (MM), they continue to secrete clonal immunoglobulins in the vast majority of cases.”
BackgroundNagao, T., Okura, T., Miyoshi, K., Watanabe, S., Manabe, S., Kurata, M., Irita, J., Fukuoka, T., & Higaki, J. (2005) · Clinical and Experimental Nephrology · doi:10.1007/s10157-005-0361-z · Cited by 13
“presence of serum monoclonal protein at a concentration of 3g/dl or less, no monoclonal protein or only a moderate amount of monoclonal light chain in the urine, the absence of lytic bone lesions, anemia, hypercalcemia, renal insufficiency related to the monoclonal protein, and a proportion of plasma cells in the bone…”
BackgroundNakagawa, N., Ota, H., Tanabe, Y., Kabara, M., Matsuki, M., Chinda, J., Sakamoto, N., Fujino, T., Takehara, N., Takeuchi, T., et al. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.4857 · Cited by 13
“The cumulative probability of progression of monoclonal gammopathy to myeloma or related plasma cell disorder has been reported as 10% at ten years, 21% at 20 years, and 26% at 25 years following diagnosis (7).”
BackgroundMultiple myeloma (pathogenesis, clinical features, diagnosis, differential diagnosis). Part I
Бессмельцев, С. С. (2013) · Clinical oncohematology · doi:10.21320/2500-2139-2013-6-3-237-257 · Cited by 24
Bustoros, M. W., Kastritis, E., Sklavenitis‐Pistofidis, R., Liu, C., Hornburg, K., Kanellias, N., Kim, P. G., Liu, D., Gavriatopoulou, M., Marinac, C. R., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25441 · Cited by 14
“Patients with IgA and IgM-type disease were excluded, given their established higher risk of progression.(8) M-protein was measured by serum protein electrophoresis (SPEP) and confirmed by immunofixation.”
BackgroundMethodSpäth, F., Wibom, C., Krop, E. J. M., Izarra, A., Johansson, A.-S., Bergdahl, I. A., Hultdin, J., Vermeulen, R. C. H., & Melin, B. S. (2019) · Haematologica · doi:10.3324/haematol.2019.216895 · Cited by 13
“Overview of the pre-diagnostic samples for each included case (1-65) with respect to disease status during the study period.”
MethodMcShane, C. M., Murphy, B., Santin, O., & Anderson, L. A. (2019) · BMC Family Practice · doi:10.1186/s12875-019-0944-5 · Cited by 13
“5–1%, and remains elevated beyond 25 years of observation [9, 10].”
BackgroundSchmidt, B., Debold, E., Frank, M., Arendt, M., Dragano, N., Dürig, J., Dührsen, U., Moebus, S., Erbel, R., Jöckel, K., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03825-5 · Cited by 14
Allen, H. C., & Sharma, P. (2021) · StatPearls · Cited by 31
Epidemiological Evidence: IgE, Allergies, and Hematopoietic Malignancies
Martínez-Maza, O., Moreno, A. D., & Cozen, W. (2009) · Humana Press eBooks · doi:10.1007/978-1-60761-451-7_5 · Cited by 14
Caers, J., Vekemans, M., Bries, G., Beel, K. A., Delrieu, V., Deweweire, A., Demuynck, H., Prijck, B. D., Samblanx, H. D., Kentos, A., et al. (2013) · Annals of Medicine · doi:10.3109/07853890.2013.801562 · Cited by 14
Global Gene Expression Profiling in the Study of Multiple Myeloma
Shaughnessy, J. D. (2003) · International Journal of Hematology · doi:10.1007/bf02983777 · Cited by 14
“GEP signatures suggest that MGUS cannot be distinguished from MM [9], yet this PC dyscrasia rarely converts to overt MM [ 15 ].”
BackgroundInfluentialLadetto, M., Mantoan, B., Marco, F. D., Drandi, D., Aguzzi, C., Astolfi, M., Vallet, S., Ricca, I., Aquila, M. D., Pagliano, G., et al. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.08.008 · Cited by 13
Maciocia, N., Wechalekar, A. D., & Yong, K. (2016) · Hematological Oncology · doi:10.1002/hon.2345 · Cited by 16
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia
Tedeschi, A., Conticello, C., Rizzi, R., Benevolo, G., Laurenti, L., Petrucci, M. T., Zaja, F. F., & Varettoni, M. (2018) · Hematological Oncology · doi:10.1002/hon.2539 · Cited by 16
“3% of the population older than 70 years.(1) Roughly 15% of individuals with MGUS has the IgM subtype.”
BackgroundGutierrez, N. C., García‐Sánz, R., & Miguel, J. F. S. (2007) · Clinical & Translational Oncology · doi:10.1007/s12094-007-0114-4 · Cited by 17
“8% annual risk of malignant transformation [1, 2].”
Mohite, P. B., Puri, A. V., Pandhare, R., Singh, S. K., & Prajapati, B. G. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673274455231219044728 · Cited by 12
Samur, A. A., Corre, J., Talluri, S., Shah, P. S., Graffeuil, A., Rivera, J., Fan, Y., Dakiki, B., Szalat, R. E., Fulciniti, M., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00289 · Cited by 12
Treatment of newly diagnosed multiple myeloma: advances in current therapy
Kumar, S. K. (2009) · Medical Oncology · doi:10.1007/s12032-009-9370-1 · Cited by 13
“The risk of progression of MGUS is approximately 1% per year, and remains unchanged throughout the course of the disease [ 11 ].”
BackgroundClinicopathological significance and potential drug target of p15INK4B in multiple myeloma
Li, J., Hou, Lin, Y., Lu, Z., & Bi, L. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s71088 · Cited by 12
“MGUS is considered as the precursor of MM, since it is able to progress to symptomatic MM at a rate of 1% per year.(10) MGUS plasma cells share many abnormal characteristics with MM plasma cells.”
Horike, K., Takeda, A., Tsujita, M., Goto, N., Watarai, Y., Uchida, K., Katayama, A., Nishihira, M., Shimizu, A., Nozu, K., et al. (2018) · Nephrology · doi:10.1111/nep.13278 · Cited by 12
“those over 50 years of age and 5% over 70 years have a monoclonal protein.(10) Patients with hereditary amyloidosis”
BackgroundAutoimmune Manifestations in Patients With Waldenström Macroglobulinemia
Bockorny, B., Atienza, J., & Dasanu, C. A. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.04.009 · Cited by 12
“The diagnosis of IgM monoclonal gammopathy of uncertain significance (MGUS) increases the risk of WM 46-fold.(9,10) In addition, family history of at least one first-degree relative with either WM or another B-cell disorder has been found in 18.”
Proteomic analysis of multiple myeloma: Current status and future perspectives
Ge, F., Bi, L., Tao, S., Xu, X., Zhang, Z., Kitazato, K., & Zhang, X. (2010) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201000044 · Cited by 12
“A multistep development model suggests that monoclonal gammopathy of undetermined clinical significance (MGUS) might become smouldering MM, and ultimately symptomatic intramedullary and extramedullary MM, or plasma cell leukemia [3].”
Golombick, T., DIAMOND, T. H., Manoharan, A., & Ramakrishna, R. (2015) · Integrative Cancer Therapies · doi:10.1177/1534735415622013 · Cited by 12
“The risk of progression to symptomatic MM is markedly higher in SMM compared with MGUS, 10% per year versus 1% per year, respectively.(11) Despite these findings, the cornerstone of managing multiple myeloma precursor disease involves a “watch and wait” strategy.”
BackgroundPika, T., Lochman, P., Sandecká, V., Maisnar, V., Minařík, J., Tichý, M., Zapletalová, J., Solcova, L., Ščudla, V., & Hájek, R. (2015) · Neoplasma · doi:10.4149/neo_2015_100 · Cited by 12
Metadata
- Authors
- Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J.
- Affiliations
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-02-21
- Volume
- 346
- Issue
- 8
- Pages
- 564-569
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2000655497
- Cited by
- 1,475
- References
- 17
- Citations by year
- 2026: 32 · 2025: 51 · 2024: 66 · 2023: 48 · 2022: 62 · 2021: 65 · 2020: 66 · 2019: 56 · 2018: 67 · 2017: 62 · 2016: 59 · 2015: 63 · 2014: 74 · 2013: 87 · 2012: 63
- FWCI
- 23.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA6 2242, P01CA062242)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- monoclonal gammopathy of undetermined significance, progression to multiple myeloma, prognosis, plasma cell neoplasms, AL amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, plasmacytoma, smoldering multiple myeloma, bone marrow plasma cells, risk prediction
- MeSH terms
- Adult, Aged, Amyloidosis, Follow-Up Studies, Humans, Leukemia, Lymphoid, Lymphoma, Waldenstrom Macroglobulinemia, Middle Aged, Multiple Myeloma, Paraproteinemias, Probability, Prognosis, Risk Factors, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.